Benchmark Reiterates "Buy" Rating for Surgery Partners (NASDAQ:SGRY)
Surgery Partners (NASDAQ:SGRY – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at Benchmark in a research note issued on Wednesday, Benzinga reports. They currently have a $50.00 price objective on the stock. Benchmark’s price target indicates a potential upside of 103.83% from the company’s current price. A number of other […]